<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745144</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0031</org_study_id>
    <secondary_id>2018-001015-70</secondary_id>
    <nct_id>NCT03745144</nct_id>
    <nct_alias>NCT04086225</nct_alias>
  </id_info>
  <brief_title>Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®</brief_title>
  <official_title>A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potential effects of cladribine on the
      pharmacokinetics of monophasic oral contraceptive microgynon® by assessment of its
      constituents, ethinyl estradiol (EE) and levonorgestrel (LNG).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">January 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Plasma Concentration Time Curve From Zero to Tau at Steady State (AUCtau,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration From Time Zero to Tau at Steady State (Cmin,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at End of Dosing Interval at Steady State (Ctrough) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration at Steady State (Cave,ss) of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-to-Trough Fluctuation Over One Complete Dosing Interval at Steady State of Ethinyl Estradiol and Levonorgestrel</measure>
    <time_frame>Pre-dose up to 24 hour (Day 15) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Cladribine</measure>
    <time_frame>Pre-dose up to 2.0 hour post-dose on Days 10, 11, 12, and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (tmax) of Cladribine</measure>
    <time_frame>Pre-dose up to 2.0 hour post-dose on Days 10, 11, 12, and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Electrocardiogram (ECG) and Laboratory Findings</measure>
    <time_frame>Up to Day 84</time_frame>
    <description>Number of participants with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Relapsing Multiple Sclerosis (RMS)</condition>
  <arm_group>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants will receive cladribine once-daily for 5 consecutive days in treatment period 1 and 2.</description>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.</description>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon®</intervention_name>
    <description>Participants will receive Microgynon® tablet once daily for 21 days in treatment period 1 and 2.</description>
    <arm_group_label>First Cladribine, Then Placebo</arm_group_label>
    <arm_group_label>First Placebo, Then Cladribine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are pre-menopausal women with or without child-bearing potential with a negative serum
             pregnancy test, and women with child-bearing potential receiving adequate birth
             control

          -  Participants with diagnosis of clinically stable and definite relapsing multiple
             sclerosis (RMS)

          -  Adequate hematological, hepatic and renal function as defined in the protocol

          -  Are able and willing to accept dietary restrictions and restrictions regarding the use
             of concomitant medications (including over-the-counter products, herbal medicines and
             dietary supplements) over the course of the study

          -  Have a body weight and body mass index (BMI) within the range at screening

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  History of clinically relevant allergy or known hypersensitivity to the active
             substance or to any of the excipients of cladribine tablets or hypersensitivity to
             drugs with a similar chemical structure to cladribine - History of clinically relevant
             allergy or known hypersensitivity to 1 of the active substances levonorgestrel (LNG)
             or ethinylestradiol (EE) or to any excipients of Microgynon® tablets

          -  Positive results from serology examination for Hepatitis B surface antigen (HbsAg) not
             due to vaccination, hepatitis B core antibody (HbcAb), Hepatitis C virus antibody
             (anti- HCV) or Human Immunodeficiency antibody (anti-HIV)

          -  Presence or risk of venous thromboembolism (VTE) arterial thromboembolism (ATE)

          -  Diabetes mellitus (Type 1 or Type 2) with vascular manifestations

          -  Signs or symptoms of neurological disease other than multiple sclerosis (MS) that
             could explain the symptoms of the participant

          -  Presence of gastrointestinal (GI) disease or history of gastrointestinal -tract
             surgery

          -  Exposure to another investigational drug within the last 2 months or within last 6
             month if agent is known to be immunosuppressive

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Josef und St. Elisabeth Hospital gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroPoint</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Neurologie Dietenbronn GmbH - Diagnostisches und therapeutisches Kompetenzzentrum für Multiple Sklerose</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.A. - LEK A.M.Maciejowscy SC.</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioResearch Group Sp. z o. o</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKARDIA Hospital Cardiology</name>
      <address>
        <city>Nałęczów</city>
        <zip>24-140</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp</name>
      <address>
        <city>Otwock</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Cladribine</keyword>
  <keyword>Microgynon®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

